AddedRisk Factors
Additionally, our Bylaws provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The choice of forum provisions may increase costs to bring a claim, discourage claims or limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company or the Company’s directors, officers or other employees, which may discourage such lawsuits against the Company or the Company’s directors, officers and other employees. Alternatively, if a court were to find the choice-of-forum provisions contained in the Bylaws to be inapplicable or unenforceable in an action, the Company may incur additional costs associated with resolving such action in other jurisdictions. The exclusive forum provisions in the Bylaws will not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the federal securities laws including the Exchange Act or the Securities Act, as amended, or the respective rules and regulations promulgated thereunder.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedRisk Factors
The Company expects to incur substantial expenses related to the integration of NuVasive and may be unable to realize the anticipated synergies, which could adversely affect the Company’s business, financial condition and results of operations.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
We depend on a limited number of sources of human tissue for use in some of our regenerative biologics products and a limited number of entities to process the human tissue for use in those regenerative biologics products, and any failure to obtain tissue from
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
As of December 31, 2024, we had outstanding $450.0 million aggregate principal amount of our 0.375% Convertible Senior Notes due March 15, 2025, (the “2025 Notes”). This significant amount of debt has important risks to us and our investors, including:
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
requiring a portion of our cash flow from operations to make principal and interest payments on this debt;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
increasing our vulnerability to general adverse economic and industry conditions;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
reducing the cash flow available to fund capital expenditures and other corporate purposes and to grow our business;
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
limiting our flexibility in planning for, or reacting to, changes in our business and the industry; and
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
limiting our ability to borrow additional funds as needed or take advantage of business opportunities as they arise.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our rapid growth has placed, and will continue to place, a significant strain on our management and on our operational and financial resources and systems. Failure to manage our growth effectively could cause us to over-invest or under-invest in infrastructure, and result in losses or weaknesses in our infrastructure, which could materially adversely affect us. Additionally, our anticipated growth will increase the demands placed on our suppliers, resulting in an increased need for us to carefully monitor for quality assurance. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
On February 1, 2025, President Trump announced the imposition of additional substantial tariffs on imports from various countries, including China, Canada and Mexico, and the subject countries indicated their intention to impose counter measures. Under the announced measures, a 25% tariff will be applied to steel and aluminum products from Canada and Mexico, while a 10% tariff will be imposed on steel and aluminum imports from China.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
The Company expects to incur substantial expenses related to the integration of NuVasive and may be unable to realize the anticipated synergies, which could adversely affect the Company’s business, financial condition and results of operations.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedRisk Factors
As a result of the NuVasive Merger, the Company may experience impacts on relationships with contractual counterparties (such as business partners, surgeons, vendors, sales representatives, contractors, distributors or other third-party service providers) that may harm the Company’s business and results of operations. Certain counterparties may seek to terminate or modify contractual obligations following the NuVasive Merger whether or not contractual rights are triggered as a result of the NuVasive Merger. There can be no guarantee that Globus’s or NuVasive’s contractual counterparties will remain with or continue to have a relationship with the Company or do so on the same or similar contractual terms following the NuVasive Merger. If any contractual counterparties (such as business partners, surgeons, vendors, sales representatives, contractors, distributors or other third-party service providers) seek to terminate or modify contractual obligations or discontinue their respective relationships with the Company, then the Company’s business and results of operations may be harmed.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedRisk Factors
Our business could suffer if we lose the services of key members of our senior management, key advisors or personnel. personnel, and if we do not successfully manage the transition associated with the resignation of our former chief executive officer and the appointment of our new chief executive officer, it could have an adverse impact on our business.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Accordingly, while we remain a controlled company and during any transition period following a time when we are no longer a controlled company, you will not have the same protections afforded to stockholders of companies that are subject to all of the New York Stock Exchange’s corporate governance requirements.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
A determination that we have failed to comply, whether knowingly or inadvertently, may result in substantial penalties, including fines and enforcement actions and civil and/or criminal sanctions, the disgorgement of profits and the imposition of a court-appointed monitor, as well as the denial of export privileges, and may have an adverse effect on our reputation.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Reimbursement and healthcare payment systems in international markets vary significantly by country, and include both government-sponsored healthcare and private insurance. insurance and generally have lower prices and more restrictive reimbursement conditions than in the U.S.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
If implemented, these Specifically, changes to tariffs and countermeasures trade policies have and could increase continue to impact the cost of raw materials and components necessary for our operations, disrupt our global supply chain and create additional operational challenges.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Patent litigation is highly prevalent in the medical device industry is characterized by patent litigation industry, and we could become subject to litigation that could be costly, result in the diversion of management’s time and efforts, require us to pay damages, and/or prevent us from marketing our existing or future products.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
From time to time we We have acquired, and expect to consider opportunities in the future to acquire or make investments in other in, technologies, products and businesses that may enhance our capabilities, complement our current products or expand the breadth of our markets or customer base.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
We operate in a very competitive business environment and if we are unable to compete successfully against our existing or potential competitors, our sales sales, operating results, and operating results growth may be negatively affected and we may not grow. affected.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
The techniques used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world, including countries that engage in state-sponsored cyber attacks.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Shifts As discussed in greater detail below, shifts in governmental policies including tariffs, trade policies or regulations in various jurisdictions have and could continue to increase the cost of raw materials and components necessary for our operations, disrupt supply chains and negatively impact profitability.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
Integrating the NuVasive business acquired businesses into Globus may be more difficult, costly or time-consuming than expected and the Company may fail to realize the anticipated benefits of the NuVasive Merger, such acquisitions, which may adversely affect the Company’s business results and negatively affect the value of the Company’s Class A common stock.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedRisk Factors
EU CE markings for medical devices will continue to be recognized in Great Britain until June 30, 2028, and certificates issued for medical devices by EU-recognized EU-designated Notified Bodies will continue to be valid for the Great Britain market until June 30, 2028 and 2028; however the EU no longer recognizes UK Notified Bodies, now known as Approved Bodies.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As a result, we currently lack the breadth of published long-term clinical data supporting the safety and efficacy of virtually all many of our products and the benefits they offer that might have been generated in connection with other approval processes.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
treat chronic pain. Our neuromonitoring services use proprietary software-driven nerve detection and avoidance technology and include intraoperative neuromonitoring (“IONM”) services to aid spine surgery.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
Restructuring costs represent costs associated with the Company’s plans to optimize the organizational structure, merge synergies and leverage the strength of both commercial organizations.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The $16.5 million, or 10.1%, decrease in research and development expenses for the year ended December 31, 2025 was primarily driven by a decrease of $21.9 million in employee-related expenses, excluding Nevro employee-related expenses, and a decrease of $12.6 million in acquired intellectual property research and development. This decrease was partially offset by an increase of $15.2 million for Nevro research and development expenses.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The increase of $197.1 million, or 20.1%, in selling, general and administrative expenses for the year ended December 31, 2025 was primarily driven by an increase of $160.2 million for Nevro expenses. Additionally, there was an increase of $37.4 million in provision for litigation driven by the accrual of $43.1 million in the third quarter of the year ended December 31, 2025 related to the Pimenta Litigation (as defined in Note 15, Commitments and Contingencies in “Item 8. Financial Statements and Supplementary Data”) offset by $5.7 million of various net settlements received.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The decrease in restructuring costs of $8.7 million compared to the same period of the prior year was primarily due to lower employee termination benefit expenses from the 2024 Synergy Plan and the 2025 Strategic Integration Plan (each as defined in Note 16, Restructuring And Other Costs in “Item 8. Financial Statements and Supplementary Data”) during the year ended December 31, 2025 compared to the expenses from the 2024 Synergy Plan for the year ended December 31, 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
The increase of $117.7 million was due to the bargain purchase gain related to the Nevro Merger as of December 31, 2025.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
interest expense due to a shorter outstanding period of the 2025 Notes (as defined in “Item 7A. Quantitative and Qualitative Disclosure About Market Risk”) in the current period compared to the prior period. Further, there was an increase of $2.4 million from gain on cost method investments. This was partially offset by a decrease in interest income of $8.2 million due to a lower average balance across the Company’s marketable securities, cash and cash equivalents in the current period as compared to the prior period.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
AddedMD&A
For the year ended December 31, 2025, the decrease in the effective tax rate was primarily due to the release of valuation allowances on certain deferred tax assets of $46.3 million and the impact of the non-taxable bargain purchase gain of $117.7 million in the second quarter of the year ended December 31, 2025, with no comparable event in the prior period.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RemovedMD&A
We record a provision for litigation settlements when a loss is known or considered probable and the amount can be reasonably estimated and in the case of a favorable settlement, income when realized.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
The $39.7 million or 32.0% increase in research and development expenses shows our continued investment in product development. This increase was primarily driven by increased personnel-related expenses of $24.0 million due to increased headcount and $12.6 of IPR&D expense recorded in the current period from an acquisition.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
The increase of $337.6 million or 52.5% in selling, general and administrative expenses was primarily driven by increases to personnel-related expenses of $251.1 million due to increased headcount primarily from the NuVasive Merger, as well as increases to professional fees of $23.8 million, consulting and outside service expenses of $13.6 million, and rent expenses of $14.3 million.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
The provision for litigation was consistent for the year ended December 31, 2024, as compared to the provision expense recorded during the year ended December 31, 2023.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
The decrease in the effective tax rate is primarily due to windfall benefits, reserve releases, and internal reorganization, as a percentage of pretax earnings.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
A discussion of our Results of Operations for the year ended December 31, 2023 can be found in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations: Results of Operations; Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022.” on our Form 10-K filed on February 20, 2024.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
In connection with the NuVasive Merger, the Company acquired additional obligations and commitments, including, but not limited to (i) the 2025 Notes, with a principal balance of $450.0 million, (ii) contingent consideration arrangements associated with certain historical NuVasive acquisitions, and (iii) operating lease and finance lease obligations. Refer to the Notes to the consolidated financial statements for further description of our 2025 Notes (Note 11), contingent consideration arrangements (Notes 6 and 15), and lease obligations (Note 17).
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
(2) In connection with certain acquisitions completed in 2011 through 2024, we have certain contingent consideration obligations payable to the sellers in these transactions upon the achievement of certain regulatory and sales milestones. For further information, see Notes 3, and 6 to the consolidated financial statements in “Part II; Item 8. Financial Statements and Supplementary Data.”
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RemovedMD&A
A discussion of our cash flows for the year ended December 31, 2023 can be found in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations: Results of Operations; Cash Flows.” On our Form 10-K filed on February 20, 2024.
Read it in 10-K Feb 20, 2025 at sec.govopen_in_new
RewordedMD&A
The higher cash used in investing activities for the year ended December 31, 2024 2025 was primarily due primarily to decreases an increased outflow of $234.9 million in marketable securities net inflows acquisition of $720.3 million as we manage our liquidity, as well as increased businesses and an increase in purchases of property and equipment of $37.2 million primarily driven $49.3 million, partially offset by increased production resulting from the NuVasive Merger. sales of marketable securities of $103.8 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
(“Merger Sub”), (“Nevro”) and Palmer Merger Sub, Inc., a wholly owned subsidiary of the Company, Company (“Palmer Merger Sub”), Palmer Merger Sub merged with and into NuVasive, Nevro (the “Nevro Merger” and, together with the NuVasive Merger, the “NuVasive and Nevro Mergers”), with Nevro surviving as a wholly owned subsidiary of the Company (the “NuVasive Merger”). Company.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The higher net cash provided by operating activities for the year ended December 31, 2024 2025 was primarily the result of higher net income after adjusting out non-cash add-backs of $434.9 million, favorable changes in deferred income taxes of $144.5 million and non-cash expenses, primarily due to the NuVasive Merger. favorable changes in accounts receivable of $25.9 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
The lower net cash used in financing activities for the year ended December 31, 2024 2025 was primarily the result of decreased the repayment of the 2025 Notes for $450.0 million and increased repurchases of Class A Common common stock of $139.8 $214.7 million, and higher proceeds from the exercise of stock options of $98.0 million partially offset by increased decreased payments of business acquisition-related liabilities of $37.6 $30.0 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Our cost of sales consists primarily of costs from our in-house manufacturing, costs of products purchased from third-party suppliers, excess and obsolete inventory charges, depreciation of surgical instruments and cases, royalties, shipping, inspection and related costs incurred in making our products available for sale or use.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Regionally, the increase was driven by From a geographic standpoint, sales growth in the Europe and Middle East region increased by $116.9 $49.9 million, the Latin America region by $26.8 million and sales in the Asia Pacific region increased by $87.2 $4.6 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Domestic enabling technology Further, there was a decrease in domestic Enabling Technology sales increased by $36.2 of $17.3 million compared to the same period in the prior year, primarily driven by higher lower unit placement.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Amortization of intangibles increased decreased by $68.3 million $1.2 million, or 133.9% 1.0%, for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023, due to the impact of the intangibles acquired from the NuVasive Merger. 2024.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, Change (In thousands, except percentages) 2025 2024 2023 $ % Amortization of intangibles Bargain purchase gain $ 119,373 117,704 $ 51,032 $ 68,341 133.9% 117,704 100.0% Percentage of net sales 4.7% 3.3% 4.0 % —%
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, Change (In thousands, except percentages) 2025 2024 2023 $ % Acquisition-related costs Other income/(expense), net $ 29,623 7,548 $ 68,274 (45,269) $ (38,651) -56.6% 52,817 (116.7 Percentage of net sales 1.2% 4.4% 0.3 % (1.8
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
From a product standpoint, the increase was mainly due to musculoskeletal solutions primarily driven by Nevro sales increases of $231.3 million, primarily due to spine products. $39.4 million.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
RewordedMD&A
We may also request Swingline Loans (as defined in the September 2023 Credit Agreement) at either the Base Rate or the Daily Term SOFR Rate. Rate (each as defined in the September 2023 Credit Agreement).
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
The composite income tax rate, tax provisions, deferred tax assets and deferred tax liabilities will vary according to the jurisdiction in which profits arise.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new
Quiet changesMD&A
Goodwill is tested for impairment at least annually or whenever events or circumstances indicate that a carrying amount may not be impaired. recoverable.
Read it in 10-K Feb 24, 2026 at sec.govopen_in_new